NCT06698692View on ClinicalTrials.gov

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

April 2, 2025

Conditions
ESCC
Interventions
DRUG

Trilaciclib Injection [Cosela]

Trilaciclib Combined chemoradiotherapy

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER